Literature DB >> 18321749

Critical contribution of immunoproteasomes in the induction of protective immunity against Trypanosoma cruzi in mice vaccinated with a plasmid encoding a CTL epitope fused to green fluorescence protein.

Bin Chou1, Hajime Hisaeda, Jianying Shen, Xuefeng Duan, Takashi Imai, Liping Tu, Shigeo Murata, Keiji Tanaka, Kunisuke Himeno.   

Abstract

Acquired immunity against infection with Trypanosoma cruzi is dependent on CD8(+)T cells. Here, to develop a vaccine strategy taking advantage of activated CD8(+)T cells, we constructed a DNA vaccine, designated pGFP-TSA1, encoding a fusion protein linking GFP to a single CTL epitope of TSA1, a leading candidate for vaccine against T. cruzi. C57BL/6 mice vaccinated with this plasmid showed suppressed parasitemia and prolonged survival. Vaccination with pGFP-TSA1 enhanced epitope-specific cytotoxicity and IFN-gamma secretion by CD8(+)T cells. Furthermore, the depletion of CD8(+)T cells prior to challenge infection with T. cruzi completely abolished this protection, indicating that CD8(+)T cells are the principal effector T cells involved. When mice deficient in the proteasome activator PA28alpha/beta or the immunoproteasome subunits LMP2 and LMP7 were used, the protective immunity against infection was profoundly attenuated. Our findings clearly demonstrate that vaccination with pGFP-TSA1 successfully induces protection dependent on CD8(+)T cell activation, in which immunoproteasomes play a crucial role. It is noteworthy to document that physical binding of the epitope and GFP is required for induction of this protection, since mice vaccinated with pTSA1-IRES-GFP failed to acquire resistance, probably because the epitope and GFP are separately expressed in the antigen-presenting cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18321749     DOI: 10.1016/j.micinf.2007.11.010

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  7 in total

Review 1.  On the role of the immunoproteasome in transplant rejection.

Authors:  Michael Basler; Jun Li; Marcus Groettrup
Journal:  Immunogenetics       Date:  2018-09-15       Impact factor: 2.846

Review 2.  Dysfunction in protein clearance by the proteasome: impact on autoinflammatory diseases.

Authors:  Anja Brehm; Elke Krüger
Journal:  Semin Immunopathol       Date:  2015-05-12       Impact factor: 11.759

3.  Trypanosoma cruzi infection down-modulates the immunoproteasome biosynthesis and the MHC class I cell surface expression in HeLa cells.

Authors:  Ricardo Camargo; Liliam O Faria; Alexander Kloss; Cecília B F Favali; Ulrike Kuckelkorn; Peter-Michael Kloetzel; Cezar Martins de Sá; Beatriz D Lima
Journal:  PLoS One       Date:  2014-04-21       Impact factor: 3.240

4.  Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection.

Authors:  Anitra L Farrow; Girish Rachakonda; Linlin Gu; Valentina Krendelchtchikova; Pius N Nde; Siddharth Pratap; Maria F Lima; Fernando Villalta; Qiana L Matthews
Journal:  PLoS Negl Trop Dis       Date:  2014-08-21

5.  Fluctuations of Spleen Cytokine and Blood Lactate, Importance of Cellular Immunity in Host Defense Against Blood Stage Malaria Plasmodium yoelii.

Authors:  Takashi Imai; Kazutomo Suzue; Ha Ngo-Thanh; Suguri Ono; Wakako Orita; Haruka Suzuki; Chikako Shimokawa; Alex Olia; Seiji Obi; Tomoyo Taniguchi; Hidekazu Ishida; Luc Van Kaer; Shigeo Murata; Keiji Tanaka; Hajime Hisaeda
Journal:  Front Immunol       Date:  2019-09-25       Impact factor: 7.561

Review 6.  On the Role of the Immunoproteasome in Protein Homeostasis.

Authors:  Michael Basler; Marcus Groettrup
Journal:  Cells       Date:  2021-11-18       Impact factor: 6.600

7.  Resistance to malaria by enhanced phagocytosis of erythrocytes in LMP7-deficient mice.

Authors:  Xuefeng Duan; Takashi Imai; Bin Chou; Liping Tu; Kunisuke Himeno; Kazutomo Suzue; Makoto Hirai; Tomoyo Taniguchi; Hiroko Okada; Chikako Shimokawa; Hajime Hisaeda
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.